Meningitis B vaccine (2026)

{
  "awards": [
    {
      "aboveThreshold": true,
      "contractPeriod": {
        "endDate": "2028-09-30T23:59:59+01:00",
        "maxExtentDate": "2030-09-30T23:59:59+01:00",
        "startDate": "2026-10-01T00:00:00+01:00"
      },
      "documents": [
        {
          "datePublished": "2025-09-09T11:08:31+01:00",
          "description": "Transparency notice on Find a Tender",
          "documentType": "awardNotice",
          "format": "text/html",
          "id": "054928-2025",
          "noticeType": "UK5",
          "url": "https://www.find-tender.service.gov.uk/Notice/054928-2025"
        }
      ],
      "hasRenewal": true,
      "id": "1",
      "items": [
        {
          "additionalClassifications": [
            {
              "description": "Vaccines",
              "id": "33651600",
              "scheme": "CPV"
            }
          ],
          "deliveryAddresses": [
            {
              "country": "GB",
              "countryName": "United Kingdom",
              "region": "UK"
            }
          ],
          "id": "1",
          "relatedLot": "1"
        }
      ],
      "mainProcurementCategory": "goods",
      "milestones": [
        {
          "dueDate": "2026-05-14T23:59:59+01:00",
          "id": "1",
          "status": "scheduled",
          "type": "futureSignatureDate"
        }
      ],
      "relatedLots": [
        "1"
      ],
      "renewal": {
        "description": "The Authority has the option to extend for a period or periods of up to an additional 24 months, subject to negotiation."
      },
      "status": "pending",
      "suppliers": [
        {
          "id": "GB-PPON-PNVC-2547-YXMP",
          "name": "GlaxoSmithKline UK Limited"
        }
      ],
      "title": "Meningitis B Vaccine (2026)",
      "value": {
        "amount": 0,
        "amountGross": 0,
        "currency": "GBP"
      }
    }
  ],
  "buyer": {
    "id": "GB-NHS-U6N4T",
    "name": "UK Health Security Agency"
  },
  "date": "2025-09-09T11:08:31+01:00",
  "id": "054928-2025",
  "initiationType": "tender",
  "language": "en",
  "ocid": "ocds-h6vhtk-059678",
  "parties": [
    {
      "additionalIdentifiers": [
        {
          "id": "PBMQ-7576-DVGW",
          "scheme": "GB-PPON"
        }
      ],
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "London",
        "postalCode": "E14 4PU",
        "region": "UKI42",
        "streetAddress": "10 South Colonnade"
      },
      "contactPoint": {
        "email": "vmc.vaccines@ukhsa.gov.uk"
      },
      "details": {
        "classifications": [
          {
            "description": "Public authority - central government",
            "id": "publicAuthorityCentralGovernment",
            "scheme": "UK_CA_TYPE"
          }
        ],
        "url": "https://www.gov.uk/government/organisations/uk-health-security-agency"
      },
      "id": "GB-NHS-U6N4T",
      "identifier": {
        "id": "U6N4T",
        "scheme": "GB-NHS"
      },
      "name": "UK Health Security Agency",
      "roles": [
        "buyer"
      ]
    },
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "London",
        "postalCode": "WC1A 1DG",
        "region": "UKI31",
        "streetAddress": "GSK HQ, 79 New Oxford Street"
      },
      "contactPoint": {
        "email": "customercontactuk@gsk.com"
      },
      "details": {
        "scale": "large",
        "vcse": false
      },
      "id": "GB-PPON-PNVC-2547-YXMP",
      "identifier": {
        "id": "PNVC-2547-YXMP",
        "scheme": "GB-PPON"
      },
      "name": "GlaxoSmithKline UK Limited",
      "roles": [
        "supplier"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "description": "The provision of a vaccine to protect against meningococcal B (MenB) disease, to be used in the national childhood immunisation programme, as well as a targeted programme to protect at risk adults against Gonorrhoea.\nThis notice provides an indication to the market of UKHSA\u0027s intention to enter into negotiations with GlaxoSmithKline (UK) Limited, with the objective of awarding a contract for the supply of the meningococcal group B vaccine, in accordance with JCVI advice.",
    "documents": [
      {
        "description": "Not published",
        "documentType": "conflictOfInterest",
        "id": "conflictOfInterest"
      }
    ],
    "id": "C352798",
    "legalBasis": {
      "id": "2023/54",
      "scheme": "UKPGA",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
    },
    "lots": [
      {
        "id": "1",
        "status": "complete"
      }
    ],
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "The following conditions are met in relation to the public contract under Schedule 5, Paragraph 5 (a, b) of the Procurement Act 2023-\n(a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and\n(b)there are no reasonable alternatives to those goods, services or works.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "singleSuppliersIntellectualPropertyExclusiveRights"
      }
    ],
    "riskDetails": "The below known unknown risks have been identified, which may require modification of the contract under paragraph 5 of Schedule 8 to the PA 2023 if one of the below identified risks materialise.\nRisk 1:\nThe COVID-19 pandemic led to lockdown events, which disrupted the distribution and uptake of some national immunisation campaigns. The forecast delivery and stock requirements were substantially changed as a result. An ongoing risk is the materialisation of a UK health emergency or global pandemic, which may materialise in any given year.\nHow the risk may impact on the performance of the contract:\nA health emergency or pandemic may materially affect the uptake of the MenB vaccine. Continued delivery of the vaccine within the original term of the contract could jeopardise stock management and effective use of vaccines before expiry.\nWhy is it not possible to address the potential impact of such risks?\nUKHSA and suppliers cannot reasonably predict the occurrence of a pandemic. UKHSA cannot determine an effective delivery schedule and contract term which would be effective during a pandemic to mitigate the risk of reduced uptake.\nThe possibility of contract modification if the risk materialises.\nIf a pandemic event or health emergency occurs, then it is highly likely that the contract may need to be modified.\nRisk 2:\nA new meningococcal strain materialises, which changes the demand for the contracted meningococcal vaccine requiring additional volumes to be procured to provide protection to expanded cohorts.\nHow the risk may impact on the performance of the contract.\nShould there be an increase in demand, then the current ordered volumes and planned delivery schedules would not provide for an expansion in the number of cohorts which need to be covered with MenB immunisations.\nWhy is it not possible to address the potential impact of such risks?\nUKHSA considers available information from experts within UKHSA, JCVI and DHSC. However, UKHSA cannot anticipate the requirements of an unknown risk. The costs to provide contingency volumes for an unknown risk would be disproportionate to the likelihood of the risk materialising.\nThe possibility of contract modification if the risk materialises:\nIt would be likely that the contract would be amended if a new meningococcal strain materialises.",
    "status": "complete",
    "title": "Meningitis B vaccine (2026)"
  }
}